CN103735689A - Application of natural medicinal composition in preparing anti-hypoxia medicines and health-care products - Google Patents
Application of natural medicinal composition in preparing anti-hypoxia medicines and health-care products Download PDFInfo
- Publication number
- CN103735689A CN103735689A CN201410025628.7A CN201410025628A CN103735689A CN 103735689 A CN103735689 A CN 103735689A CN 201410025628 A CN201410025628 A CN 201410025628A CN 103735689 A CN103735689 A CN 103735689A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- panacis quinquefolii
- eluent
- hypoxia
- herba centellae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title claims abstract description 8
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims abstract description 33
- 229930182490 saponin Natural products 0.000 claims abstract description 33
- 150000007949 saponins Chemical class 0.000 claims abstract description 33
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 239000007902 hard capsule Substances 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims abstract 2
- 239000003826 tablet Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 107
- 206010002660 Anoxia Diseases 0.000 claims description 31
- 241000976983 Anoxia Species 0.000 claims description 30
- 230000007953 anoxia Effects 0.000 claims description 30
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 29
- 229930182470 glycoside Natural products 0.000 claims description 28
- 150000002338 glycosides Chemical class 0.000 claims description 28
- 239000003480 eluent Substances 0.000 claims description 25
- 229930003944 flavone Natural products 0.000 claims description 25
- 235000011949 flavones Nutrition 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 150000002213 flavones Chemical class 0.000 claims description 23
- 238000010828 elution Methods 0.000 claims description 21
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000002481 ethanol extraction Methods 0.000 claims description 11
- 238000004064 recycling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 6
- 239000004952 Polyamide Substances 0.000 claims description 4
- 229930014626 natural product Natural products 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 26
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 abstract description 12
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 abstract description 12
- 229940022757 asiaticoside Drugs 0.000 abstract description 12
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 abstract description 12
- 230000007954 hypoxia Effects 0.000 abstract description 10
- 208000028867 ischemia Diseases 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 3
- 235000008434 ginseng Nutrition 0.000 abstract description 3
- 210000002216 heart Anatomy 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 34
- 229960004756 ethanol Drugs 0.000 description 23
- 239000013558 reference substance Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 201000006474 Brain Ischemia Diseases 0.000 description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 240000005373 Panax quinquefolius Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000589 cicatrix Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940107628 american ginseng root Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008455 cerebrovascular function Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a natural medicinal composition beneficial to hypoxia tolerance. The composition is characterized by being prepared from asiaticoside and paeoniflorin with effects of anti-inflammation anti-exudation, and ginseng saponin and total saponins of dried tangerine peel with anti-ischemia and anti-hypoxia effects. The natural medicinal composition is clear in substances and controllable in quality, and sufficiently utilizes the synergetic effect of each component. Besides consideration on anti-ischemia and anti-hypoxia substances, the prescription of the natural medicinal composition is contributed to prevention and treatment of emergent inflammatory exudation caused by ischemia and hypoxia to tissues of heart and cerebral vessels. The composition can be used for preparing oral preparations, such as hard capsules, tablets, granules, powder, pills, teabags and oral solutions, and can be used in Chinese patent medicines or health-care foods for improving hypoxia tolerance.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation method that contributes to improve anoxia endurance, belong to medical technical field.
Background technology
Oxygen is the essential condition that the mankind and many biologies are depended on for existence.The required oxygen of body vital movement is called hypoxia or anoxia in the time of can not obtaining the state of sufficient supply.Anoxia will cause organism metabolism, function, morphosis generation abnormal change even.Serious or long term hypoxia can be brought serious harm to body, finally can cause the important organs such as the body heart, brain dead because energy supply is not enough.Oxygen and hypoxia are the important topics of life sciences basic theories.The formation of hypoxia can be divided three classes: the first kind is that external environment oxygen content reduces, and makes normal physiological activity process can not absorb enough oxygen, the anoxia causing as special environments such as plateau, diving and aviations; Equations of The Second Kind refers to because disease etc. causes extraneous normal oxygen amount and can not fully arrive in body, causes the anoxia of the heart, brain and respiratory system etc.; The 3rd class is the movable requisite oxygen consumption of body, has surpassed the physiology ability of mobilization, causes relative oxygen supply not enough, is common in strenuous exercise and the amount of transfiniting work.Long-term hypoxia is the important hidden danger being detrimental to health, and severe patient even can threat to life.Therefore, medicine or the health food of research anoxia enduring have wide future develop.
The present invention is exactly the compositions that a kind of natural product that contributes to improve anoxia endurance of finding from natural plants or extract is made.Said composition is to become composition of natural products by effective ingredient innovative combination, has embodied the feature of Chinese medicine " many target spots, manifold effect ", has the effect for the treatment of both the principal and secondary aspects of a disease, to have significant breakthrough and raising from efficacy and saferry.
In the alabastrum that the colored saponin of Radix Panacis Quinquefolii is araliaceae ginseng plant's Radix Panacis Quinquefolii (Panax quinquefolium L.), extract purification and obtain.Radix Panacis Quinquefolii flower contains the compositions such as saponin, trace element, polysaccharide, fatty acid, flavone, tight equality raises total saponin up to 32.5% from Radix Panacis Quinquefolii alabastrum, and content, up to 30.09%, is 6 times of (special product researchs of American ginseng root content, the 4th phase in 1999,12-14.).Radix Panacis Quinquefolii flower boosting qi and nourishing yin, relieves inflammation or internal heat and promotes the production of body fluid, and has defying age, maintains form, function and the metabolism of the myocardial cell that lacks sugar, anoxia, antitumor, and resisting fatigue, strengthens the effects such as immunologic function.The Radix Panacis Quinquefolii flower saponin that the present invention extracts can maintain environment in normal brain by anti-cerebral ischemia anoxia, thereby the hypofunction of protecting cerebral ischemia, anoxia to cause promotes learning and memory ability.Meanwhile, also there is adjusting nervus centralis, improve the effect of myocardial ischemia reperfusion injury, to stress sexual behaviour damaged, there is protective effect.
Herba Centellae total glycosides is extract purification and obtain from the dry herb of samphire Herba Centellae Centella asiatica (L.) Urban or whole herb with root.Herba Centellae is cold in nature, and bitter in the mouth, pungent has the effect of clearing away heat-damp and promoting diuresis, removing toxic substances and promoting subsidence of swelling.Herba Centellae main component is asiaticoside, asiaticoside and Asaiticoside B.Contain in addition flavonoid, volatile oil, polyacetylene eneyne class etc., also have a small amount of asiatic acid and Madecassic acid (Zhao Yuxin etc. report Herba Centellae progress, Chinese Chinese medicine information magazine, the 9th the 8th phase of volume of August in 2002,81-84).Modern pharmacological research finds that Herba Centellae total glycosides has antiinflammatory, wound healing, prevents the effects such as cicatrix hyperplasia, is mainly used in treating various skin injurys, comprises wound cicatrix, digestive tract ulcer, scleroderma etc.; The effect such as also have in addition anti-urinary system infection, inducing tumor cell to adjust to die.Yellow bosom roc patent of invention (publication number: CN1712013A) reported that Herba Centellae total glycosides has the effect of control chronic renal failure.Song Ji human relations patent of invention (publication number: CN100588403C) reported that asiatic centella total saponins has promotion wound healing, stimulated granulation growth, promoted the effect of epidermis keratinization.The patents of invention such as Hu Gang (publication number: CN1429553A) reported that Herba Centellae total glycosides has the effect of the cyclomastopathy of preventing and treating.Zhang Shenghua research has reported that asiaticoside has the inside and outside antibacterial activity of good body, the especially effect to gynecological's urinary system infection.
Peoniflorin is from the dry root of Ranunculaceae Radix Paeoniae (Paeonia lactiflora Pall.) or river Radix Paeoniae Rubra (P. veitchii Lynch.), extract purification and obtain.Its bitter in the mouth of Radix Paeoniae, is slightly cold, and returns Liver Channel, has clearing away heat and cooling blood, the effect of dissipating blood stasis analgesia.Modern pharmacological research shows that peoniflorin has suppression of autoimmune responses, antiinflammatory, pain relieving, protect the liver, increase cardiac output, improve cardio-pulmonary function, promote learning memory disorder due to learning and memory, antagonism scopolamine, significantly improve learning memory disorder due to cerebral ischemia re-pouring, improve body microcirculating state, reduce blood viscosity, suppress the effects such as platelet aggregation of ADP induction.The report such as Wei Shoujian peoniflorin is to the protection of PC12 cell ischemia injury and Mechanism Study (Chinese tcm emergency, 2000,9 (6): 274-276.); Zhang Guangqin etc. think that peoniflorin is to the blocking effect of rat myocardial cell L calcium channel (Chinese Pharmacological Bulletin, 2003,19 (8): 863-866.); Yang Jun etc. have reported protective effect (Chinese Journal of New Drugs, 2001,10 (6): 426-428.) of peoniflorin to the PC12 cell calcium overload damage of potassium chloride and the induction of N-methyl D-Aspartic Acid; Yang Jun is studied (Medical University Of Anhui's journal, 2001,36 (2): 164.) to Radix Paeoniae Rubra total glycosides treatment ischemic cerebrovascular Function and its mechanisms; Xu Hongmei has reported Radix Paeoniae Rubra total glycosides anti thrombotic action (Anhui Chinese Medicine College journal, 2000,19 (1): 46-47.).The refined qin patent of invention of Rhizoma Zingiberis Recens (publication number: CN1857440A) reported that compositions that Radix Paeoniae Alba total glycosides, Herba Ixeritis Sonchifoliae total flavones, Fructus Hippophae total flavones form has other dysfunction, the anti-ageing disease effect of waiting for a long time that control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia cause.
Exocarpium Citri Rubrum total flavones is from the dry outer peel of rutaceae orange Citrus reticulata Blanco and variety thereof, to extract purification to obtain.Exocarpium Citri Rubrum Main Flavonoids constituents is Hesperidin, neohesperidin and naringin.There is antiinflammatory, antiviral, anticancer, mutation, antiallergic, antiulcer, analgesia, hypotensive activity, can hypercholesterolemia, reduce the formation of thrombosis, improve local microcirculation and nutrition supply.
Before the present invention completes, the compositions that the Exocarpium Citri Rubrum total flavones extracting in the peoniflorin extracting in the Herba Centellae total glycosides of also not finding to extract in the Radix Panacis Quinquefolii flower saponin, Herba Centellae of extraction from Radix Panacis Quinquefolii is spent, Radix Paeoniae Rubra and Exocarpium Citri Rubrum forms is for improving the report of anoxia endurance aspect.
Summary of the invention
The inventor is from effective substance, through repetition test, selected the raw material that can be used for health food of four kinds of Ministry of Public Health regulations such as Radix Panacis Quinquefolii flower, Herba Centellae, Radix Paeoniae Rubra, Exocarpium Citri Rubrum, utilize the Radix Panacis Quinquefolii flower saponin, Herba Centellae total glycosides, peoniflorin, the Exocarpium Citri Rubrum total flavones prescription that therefrom extract respectively, so this prescription forms very safe, for the preparation of the health food or the medicine that contribute to improve anoxia endurance, without any side effects.When choosing each raw material of the present invention and carry out combination collocation, given full play to their effects separately, and can produce synergistic action effect after reasonably combined.At prescription, form except considering ischemia resisting, anoxia material base, the present invention more outstanding contributions is to have considered prevention and the treatment of answering acute inflammation to ooze out that due to ischemia, anoxia, to cardiovascular and cerebrovascular vessel tissue, cause.To have asiaticoside, the peoniflorin of antiinflammatory exudation and have Radix Panacis Quinquefolii saponin and the Exocarpium Citri Rubrum total saponins prescription of ischemia resisting, anoxia first, this compositions has significantly different from the Western medicine on market with the single target spot of anti-hypoxia ischemia; Simultaneously contribute to improve anoxia endurance Chinese patent medicine and compare with at present existing, have activity more definite, chemical composition has obvious characteristic, and this is outstanding contributions of the present invention.
Radix Panacis Quinquefolii flower saponin strongly invigorating primordial QI, nourishing the stomach to promote the production of body fluid, has the form, function and the metabolism that maintain the myocardial cell that lacks sugar, anoxia, regulates nervus centralis, to stress sexual behaviour damaged, has a protective effect; Herba Centellae total glycosides clearing away heat-damp and promoting diuresis, removing toxic substances and promoting subsidence of swelling, have antiinflammatory, wound healing and have the effect that inflammation is oozed out in treatment pulmonary; Peoniflorin clearing away heat and cooling blood, dissipating blood stasis analgesia, has suppression of autoimmune responses, antiinflammatory, pain relieving, increases cardiac output, improves cardio-pulmonary function, significantly improves learning memory disorder due to cerebral ischemia re-pouring, improves the effect of body microcirculating state; Exocarpium Citri Rubrum total flavones has cardiac nutrition, the effect of blood vessel dilating, exudation inflammation, antioxidation, change hemorheology index.These chemical compositions are collaborative, many target spots, multipath effect mutually, and four constituents combinations are mediator's body's hypoxia tolerance comprehensively fundamentally, improves physical condition.The present invention is by protective effect, the protective effect of cardiovascular system, the impact of human body energy metabolism on anaerobic condition hyponeural system system; by raising antioxidant ability of organism, to the apoptotic antagonism of hypoxia inducible, reach and contribute to improve body anoxia endurance.There is obvious novelty and technological progress.
Another outstanding contributions of the present invention are, utilize first Radix Panacis Quinquefolii flower saponin prescription for improving the anoxia endurance of body, not only for Radix Panacis Quinquefolii flower provides a kind of new purposes but also for Radix Ginseng Resource Supply benefit growth point.Meanwhile, Radix Panacis Quinquefolii flower is high 6 times compared with saponin content in Radix Panacis Quinquefolii, has very high value, is another technological progress of the present invention.
Another outstanding contributions of the present invention are, Radix Paeoniae Rubra water extract is utilized to polyamide column and macroporous resin column series system, obtain highly purified peoniflorin; Meanwhile, first the peoniflorin obtaining is applied to improve anoxia endurance medicine or health food, there is obvious technical progress and innovation.
The invention provides the compositions that a kind of natural product that contributes to improve anoxia endurance is made, said composition comprises Radix Panacis Quinquefolii flower saponin 25-100 part, Herba Centellae total glycosides 150-400 part, peoniflorin 120-300 part, Exocarpium Citri Rubrum total flavones 150-400 part, preferably Radix Panacis Quinquefolii flower saponin is 45 parts, 300 parts of Herba Centellae total glycosidess, 180 parts of peoniflorins, 300 parts of Exocarpium Citri Rubrum total flavones, it proportionally mixes and forms that active ingredient and pharmaceutic adjuvant make.Another object of the present invention has been to provide the preparation method of the method and composition that extracts respectively Radix Panacis Quinquefolii flower saponin, Herba Centellae total glycosides, peoniflorin, Exocarpium Citri Rubrum total flavones, the method comprises: 50-95% alcohol reflux 2-3 time of (1) Radix Panacis Quinquefolii flower, each 2-3 hour, filter, filtrate recycling ethanol, obtain ethanol extraction, ethanol extraction is by the D-101 macroporous resin column of anticipating, first use deionized water eluting, discard eluent, continue and use 60-90% ethanol elution, collect eluent, reclaim ethanol, dry, obtain Radix Panacis Quinquefolii flower saponin; (2) Herba Centellae deionized water extraction 2-3 time, each 2-3 hour, filters, filtrate is concentrated, concentrated solution, by processed good D-101 macroporous resin column, is first used deionized water eluting, discards eluent, continue with the ethanol elution of 60-90%, reclaim ethanol elution, reclaim ethanol, concentrated, dry, obtain Herba Centellae total glycosides; (3) Radix Paeoniae Rubra deionized water extraction 2-3 time, each 2-3 hour, filters, filtrate is concentrated, and concentrated solution, by the polyamide column of anticipating, washes with water, collect effluent and eluent, concentrated, concentrated solution is by the macroporous resin column of anticipating, first use deionized water eluting, discard eluent, continue with the ethanol elution of 30-70%, reclaim ethanol elution, dry, obtain peoniflorin; (4) Exocarpium Citri Rubrum 50-85% alcohol reflux 2-3 time, each 2-3 hour, filters, filtrate recycling ethanol, obtains ethanol extraction, and ethanol extraction is by the AB-8 macroporous resin column of anticipating, first use deionized water eluting, discard eluent, then use 10-25% ethanol elution, discard eluent, continue and use 60-90% ethanol elution, collect eluent, reclaim ethanol, dry, obtain Exocarpium Citri Rubrum total flavones; (5) by Radix Panacis Quinquefolii flower saponin 25-100 part, Herba Centellae total glycosides 150-400 part, peoniflorin 120-300 part, Exocarpium Citri Rubrum total flavones 150-400 part, after mix homogeneously, adds adjuvant even, obtains.
For realizing above technical scheme, the content of the content of Radix Panacis Quinquefolii flower saponin, Herba Centellae total glycosides content, peoniflorin, Exocarpium Citri Rubrum total flavones is measured by the following method:
The content assaying method of Radix Panacis Quinquefolii flower saponin
The preparation precision of reference substance solution takes ginsenoside Rb1's reference substance 10.0mg, puts in 10mL measuring bottle, adds anhydrous alcohol solution and is diluted to scale, shakes up, and obtains.
Test sample 50.0mg is got in the preparation of need testing solution, puts in 50mL measuring bottle, adds anhydrous alcohol solution and is diluted to scale, shakes up, and obtains.
Algoscopy precision measures reference substance solution and each 50 μ l of need testing solution, puts respectively in tool plug test tube, take dehydrated alcohol as blank, respectively evaporate to dryness; Respectively add 5% vanillin-glacial acetic acid solution 0.2ml, perchloric acid 0.8ml, airtight, shake up in rearmounted 70 ℃ of water-baths 20 minutes, taking-up is chilled to room temperature, add ethyl acetate 5ml, after shaking up, according to spectrophotography (appendix V B of < < Chinese Pharmacopoeia > > version in 2000), at wavelength 560nm place, measure respectively trap, calculate.
Exocarpium Citri Rubrum Determination Method of Flavone Content
The preparation of reference substance solution: precision takes control substance of Rutin 10.0mg, puts in 50mL measuring bottle, adds anhydrous alcohol solution and is diluted to scale, shakes up, and obtains.
The preparation of standard curve: get reference substance 10mg, with dehydrated alcohol, be mixed with every 1mL containing the solution of 0.2mg, get successively 0.1mL, 0.2 mL, 0.4 mL, 0.8 mL, 1.6mL are placed in 10mL volumetric flask, precision adds 1%AlCl3 solution 3mL, uses dehydrated alcohol standardize solution, shakes up rear room temperature and places 30min, retinue is blank, in wavelength 370nm place, survey trap, take content as abscissa, trap is vertical coordinate drawing standard curve.
Test sample 10.0mg is got in the preparation of need testing solution, puts in 50mL measuring bottle, adds anhydrous alcohol solution and is diluted to scale, shakes up, and obtains.
Algoscopy precision measures need testing solution 0.3mL, puts in 10mL measuring bottle, and precision adds 1%AlCl3 solution 3mL, uses dehydrated alcohol standardize solution, shakes up rear room temperature and places 30min, and retinue is blank.According to spectrophotography, at wavelength 370nm place, measure respectively trap, calculate.
The content assaying method of peoniflorin
Take octadecylsilane chemically bonded silica as filler; With methanol: 0.05mol/L potassium dihydrogen phosphate=40:65; Flow velocity: 1mL/min; Column temperature: 25 ℃; Sample size: 10 μ L; Detect wavelength: 230nm.Number of theoretical plate calculates and is not less than 3000 by peoniflorin peak.
Reference substance solution preparation: the about 10mg of peoniflorin reference substance of dry 36h in the phosphorus pentoxide vacuum drying apparatus of learning from else's experience, put in 25mL measuring bottle, accurately weighed, add dissolve with methanol, and be diluted to scale, shake up, obtain peoniflorin reference substance solution.
Need testing solution preparation: get the about 50mg of test sample, accurately weighed, put in 100mL measuring bottle, with dissolve with methanol and be diluted to scale, shake up, obtain need testing solution.
Assay method is accurate reference substance solution and each 10 μ L of need testing solution of drawing respectively, and injection liquid chromatography, measures, and obtains.
Herba Centellae total glycosides content assaying method
Take octadecylsilane chemically bonded silica as filler; With acetonitrile: 2mmol/L betacyclodextrin solution=24:76; Flow velocity: 1mL/min; Column temperature: room temperature; Sample size: 10 μ L; Detect wavelength: 205nm.Number of theoretical plate calculates and is not less than 4000 by asiaticoside peak.
Reference substance solution preparation: get asiaticoside reference substance and each 10mg of asiaticoside reference substance, put in 50mL measuring bottle, accurately weighed, add dissolve with methanol, and be diluted to scale and obtain reference substance solution.
Test sample 25mg is got in the preparation of need testing solution, puts in 50mL measuring bottle, with dissolve with methanol and be diluted to scale, shakes up, and obtains.
Assay method is accurate reference substance solution and each 10 μ L of need testing solution of drawing respectively, and injection liquid chromatography, measures, and obtains.
Another object of the present invention has been to provide compositions that Radix Panacis Quinquefolii flower saponin, Herba Centellae total glycosides, peoniflorin and the Exocarpium Citri Rubrum total flavones of said extracted form and has helped improve the medicine of anoxia endurance and the application in health food being prepared with.Because disclosing the compositions being comprised of Radix Panacis Quinquefolii flower saponin, Herba Centellae total glycosides, peoniflorin and Exocarpium Citri Rubrum total flavones first, the present invention there is the effect that contributes to improve anoxia endurance; therefore; by this compositions separately or coordinate and make medicament with other active constituent or adjuvant; so long as this medicament is used for contributing to improve anoxia endurance, all belong to protection scope of the present invention.Compositions of the present invention, when making any dosage form, all has the effect of anoxia enduring.
The compositions being comprised of Radix Panacis Quinquefolii flower saponin, Herba Centellae total glycosides, peoniflorin and Exocarpium Citri Rubrum total flavones (be called for short compositions, example 5 is prepared and obtained) has resisting oxygen lack, by following pharmacodynamic experiment, is confirmed.
This compositions is provided by Jilin Academy of Chinese Medicine Sciences's fitochemical studies.Sodium nitrite analytical pure, sodica calx, Plasma lactate test kit builds up Bioengineering Research Institute by Nanjing and produces, and lot number is 20121202.Positive reference substance medicine Radix Rhodiolae ginseng Qi capsule (lot number: 20121203, Sichuan Mai Liruo development in science and technology Co., Ltd).
160 of ICR mices, body weight 18 ~ 22g, the high-new Experimental Animal Center in Changchun provides.
50 of mices are got in each experiment, are divided into 5 groups, 10 every group.If 3 test group, 1 negative control group and 1 positive controls.The dosage of 3 test group compositionss is respectively 0.15g/kg, 0.30g/kg, 0.60g/kg, and blank group gives distilled water, and positive controls dosage is 0.60g/kg.Experiment is respectively organized gavage to sample, every day 1 time, and continuous 30d, gavage volume is 0.1ml/10g body weight.
1, this compositions is on the impact of anoxia enduring time-to-live of mice normal pressure
1h after last gives sample, puts into respectively by each group mice the 250ml port grinding bottle (1 every bottle) that fills 5g sodica calx, seals, and take respiratory arrest as dead indication, observes the mouse survival time.Experimental result is in Table 1.
This compositions of table 1 is on the impact of anoxia enduring time-to-live of mice normal pressure
With the comparison of blank group, * P < 0.05, * * P < 0.0.1
As shown in Table 1, the basic, normal, high three dosage groups of the present composition all can extend the time-to-live of mice, and the normal pressure anoxia enduring time-to-live is compared with blank group, and high, middle dosage group has significant difference.And the high dose group mouse survival time is longer than low dosage and middle dosage group mice.
2, the impact of the present composition on the poisoning time-to-live of mice sodium nitrite
1 h after last gives sample, each treated animal is pressed 240mg/kg body weight dosage lumbar injection sodium nitrite, observes the animals survived time.Experimental result is in Table 2.
The impact of table 2 present composition on the poisoning time-to-live of mice sodium nitrite
With the comparison of blank group, * P < 0.05, * * P < 0.0.1
As shown in Table 2, compare with negative control group, 3 dosage groups of the present composition all can
Obviously extend the mice poisoning time-to-live of sodium nitrite, there is significant difference.
3, the impact of the present composition on chmice acute cerebral ischemia the survival time under hypoxic condition
1h after last gives sample, each treated animal, records after mice broken end to the dwell time of breathing of dehiscing by stopwatch by broken end only immediately from cervical region.Experimental result is in Table 3.
The impact of table 3 present composition on chmice acute cerebral ischemia the survival time under hypoxic condition
With the comparison of blank group, * P < 0.05, * * P < 0.0.1
From table 3, the present composition can obviously extend chmice acute cerebral ischemia the survival time under hypoxic condition.
4, the present composition on mouse movement after the impact of blood lactic acid
In mice last, give to take a blood sample after sample 30min, then do not bear a heavy burden and after temperature is the water went swimming 10min of 30 ℃, take out immediately blood sampling again, finally the 3rd blood sampling of rest 20min.Press the Serum lactic acid content of 3 time points of kit measurement, and be calculated as follows lactic acid area under curve.Experimental result is in Table 4.
Blood lactic acid area under curve=5 * (the blood Lactate of the rear rest 20min of blood Lactate+2 * swimming of the rear 0min of blood Lactate+3 * swimming before swimming).
Table 4 present composition on mouse movement after the impact of blood lactic acid
With the comparison of blank group, * P < 0.05
From table 4, high, the middle dosage group of the present composition can obviously reduce blood lactic acid area under curve content after mouse movement.Thereby improve the energy supply level of body carbohydrate metabolism system, reduce the ratio of protein metabolism energy supply, thereby improve anti-anoxia ability.
The present invention is described in detail by the following examples, but does not mean that the present invention only limits to this, and specific embodiments is as follows:
embodiment 1,the preparation of Radix Panacis Quinquefolii flower saponin
Radix Panacis Quinquefolii flower 5kg, measures 60% alcohol reflux 2 times, each 2 hours with 10 times, filter, filtrate recycling ethanol, obtains ethanol extraction, add water to every 1ml containing 0.8g medical material, stir evenly, by the D-101 macroporous resin column of anticipating, first use 5 times of column volumes of deionized water eluting, discard eluent, continue with 4 times of column volumes of 70% ethanol elution, collect eluent, reclaim ethanol, dry, obtain Radix Panacis Quinquefolii flower saponin.With ginsenoside Rb
1for reference substance, adopt determined by ultraviolet spectrophotometry, the content of total saponins is 83.9%.
embodiment 2,the preparation of Herba Centellae total glycosides
Herba Centellae 20kg, measures deionized water extraction 2 times, each 2 hours with 10 times, filter, filtrate is concentrated into every 1ml containing 1.0g medical material, by processed good D101 macroporous resin column, first uses 5 times of column volumes of deionized water eluting, discard eluent, continue with 5 times of column volumes of ethanol elution of 70%, collect eluent, reclaim ethanol elution, dry, obtain Herba Centellae total glycosides.Take asiaticoside and asiaticoside as reference substance, adopt high effective liquid chromatography for measuring, Herba Centellae total glycosides is in asiaticoside and asiaticoside, and the total content of the two is 62.6%.
embodiment 3,the preparation of peoniflorin
Radix Paeoniae Rubra 20kg, measures deionized water extraction 3 times, each 2 hours with 8 times, filter, filtrate is concentrated into every 1ml containing 0.5g medical material, and concentrated solution is by the polyamide column of anticipating, wash 3 times of column volumes with water, collect effluent and eluent, concentrated, concentrated solution, by the D101 macroporous resin column of anticipating, is first used 4 times of column volumes of deionized water eluting, discards eluent, continue with 50% ethanol elution, reclaim ethanol elution, dry, obtain peoniflorin; Take peoniflorin as reference substance, utilize high effective liquid chromatography for measuring, the content of peoniflorin is 86.9%.
embodiment 4,the preparation of Exocarpium Citri Rubrum total flavones
Exocarpium Citri Rubrum 20kg, with 60% alcohol reflux 2 times, each 3 hours, filter, filtrate recycling ethanol, obtains ethanol extraction, ethanol extraction, by the AB-8 macroporous resin column of anticipating, is first used 3 times of column volumes of deionized water eluting, discards eluent, use again 3 times of column volumes of 20% ethanol elution, discard eluent, continue with 5 times of column volumes of 80% ethanol elution, collect eluent, reclaim ethanol, dry, obtain Exocarpium Citri Rubrum total flavones; Take rutin as reference substance, utilize determined by ultraviolet spectrophotometry, the content of total flavones is 85.7%.
embodiment 5,the preparation of capsule
Take Radix Panacis Quinquefolii flower saponin 15g, Herba Centellae total glycosides 100g, peoniflorin 60g, Exocarpium Citri Rubrum total flavones 100g, medical starch is appropriate, and mix homogeneously is granulated, and dry, granulate, incapsulates, and makes 1000, obtains.Each 1, every day 2 times.
embodiment 5,the preparation of tablet
Take Radix Panacis Quinquefolii flower saponin 15g, Herba Centellae total glycosides 100g, peoniflorin 60g, Exocarpium Citri Rubrum total flavones 100g, medical starch is appropriate, and mix homogeneously is granulated, dry, granulate, tabletting, makes 1000, obtains.Each 1, every day 2 times.
Claims (4)
1. contribute to improve a natural drug composition for anoxia endurance, it is characterized in that it is to be made by the raw material of following weight parts: Radix Panacis Quinquefolii flower saponin 25-100 part, Herba Centellae total glycosides 150-400 part, peoniflorin 120-300 part, Exocarpium Citri Rubrum total flavones 150-400 part.
2. a kind of natural drug composition that contributes to improve anoxia endurance according to claim 1, it is characterized in that it is to be made by the raw material of following weight parts: 45 parts of Radix Panacis Quinquefolii flower saponin, 300 parts of Herba Centellae total glycosidess, 180 parts of Radix Paeoniae Alba total glycosides, 300 parts of Exocarpium Citri Rubrum total flavones.
3. natural drug composition according to claim 1, its preparation method is as follows:
(1) Radix Panacis Quinquefolii flower 50-95% alcohol reflux 2-3 time, each 2-3 hour, filters, filtrate recycling ethanol, obtain ethanol extraction, ethanol extraction, by the D-101 macroporous resin column of anticipating, is first used deionized water eluting, discard eluent, use again 60-90% ethanol elution, collect eluent, reclaim ethanol, dry, obtain Radix Panacis Quinquefolii flower saponin;
(2) Herba Centellae deionized water extraction 2-3 time, each 2-3 hour, filters, filtrate is concentrated, concentrated solution, by processed good D-101 macroporous resin column, is first used deionized water eluting, discards eluent, use again the ethanol elution of 60-90%, reclaim ethanol elution, reclaim ethanol, concentrated, dry, obtain Herba Centellae total glycosides;
(3) Radix Paeoniae Rubra deionized water extraction 2-3 time, each 2-3 hour, filters, filtrate is concentrated, and concentrated solution, by the polyamide column of anticipating, washes with water, collect effluent and eluent, concentrated, concentrated solution is by the macroporous resin column of anticipating, first use deionized water eluting, discard eluent, then use the ethanol elution of 30-70%, reclaim ethanol elution, dry, obtain peoniflorin;
(4) Exocarpium Citri Rubrum 50-85% alcohol reflux 2-3 time, each 2-3 hour, filters, filtrate recycling ethanol, obtains ethanol extraction, and ethanol extraction is by the AB-8 macroporous resin column of anticipating, first use deionized water eluting, discard eluent, then use 10-25% ethanol elution, discard eluent, use again 60-90% ethanol elution, collect eluent, reclaim ethanol, dry, obtain Exocarpium Citri Rubrum total flavones;
(5) by Radix Panacis Quinquefolii flower saponin 25-100 part, Herba Centellae total glycosides 150-400 part, peoniflorin 120-300 part, Exocarpium Citri Rubrum total flavones 150-400 part, after mix homogeneously, adds adjuvant even, obtains.
4. composition of natural products according to claim 1, mixes with pharmaceutic adjuvant, makes oral formulations, and it can be any one in hard capsule, soft capsule, tablet, granule, powder, pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410025628.7A CN103735689B (en) | 2014-01-21 | 2014-01-21 | A kind of natural drug composition is preparing the application in anoxia enduring medicine and health product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410025628.7A CN103735689B (en) | 2014-01-21 | 2014-01-21 | A kind of natural drug composition is preparing the application in anoxia enduring medicine and health product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735689A true CN103735689A (en) | 2014-04-23 |
| CN103735689B CN103735689B (en) | 2016-01-20 |
Family
ID=50492804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410025628.7A Expired - Fee Related CN103735689B (en) | 2014-01-21 | 2014-01-21 | A kind of natural drug composition is preparing the application in anoxia enduring medicine and health product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735689B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104892719A (en) * | 2014-12-04 | 2015-09-09 | 陕西君碧莎制药有限公司 | Novel efficient preparation method for asiaticoside |
| CN117797066A (en) * | 2022-12-29 | 2024-04-02 | 太和康美(北京)中医研究院有限公司 | Ginseng and centella asiatica composition, and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582952A (en) * | 2004-06-09 | 2005-02-23 | 崔福贵 | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels |
| JP4315753B2 (en) * | 2003-08-29 | 2009-08-19 | 太陽化学株式会社 | Food material and manufacturing method thereof |
| CN102133278A (en) * | 2011-03-10 | 2011-07-27 | 湖南朗林生物制品有限公司 | Preparation method of 98% of paeoniflorin radix in radix paeoniae alba extract |
| CN102512468A (en) * | 2011-12-31 | 2012-06-27 | 吉林省集安益盛药业股份有限公司 | Semi-bionic and flooding extraction and preparation method for surface portion of American ginseng |
-
2014
- 2014-01-21 CN CN201410025628.7A patent/CN103735689B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4315753B2 (en) * | 2003-08-29 | 2009-08-19 | 太陽化学株式会社 | Food material and manufacturing method thereof |
| CN1582952A (en) * | 2004-06-09 | 2005-02-23 | 崔福贵 | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels |
| CN102133278A (en) * | 2011-03-10 | 2011-07-27 | 湖南朗林生物制品有限公司 | Preparation method of 98% of paeoniflorin radix in radix paeoniae alba extract |
| CN102512468A (en) * | 2011-12-31 | 2012-06-27 | 吉林省集安益盛药业股份有限公司 | Semi-bionic and flooding extraction and preparation method for surface portion of American ginseng |
Non-Patent Citations (1)
| Title |
|---|
| 陈有根等，: "陈皮类的生药学研究（提要）", 《江西中医学院学报·增刊》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104892719A (en) * | 2014-12-04 | 2015-09-09 | 陕西君碧莎制药有限公司 | Novel efficient preparation method for asiaticoside |
| CN117797066A (en) * | 2022-12-29 | 2024-04-02 | 太和康美(北京)中医研究院有限公司 | Ginseng and centella asiatica composition, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735689B (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101850066B (en) | Chinese medicinal composition granule and preparation method thereof | |
| CN101632827B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN105497515B (en) | A kind of two ginseng composition of smart stilbene with oxygen lack resistant function | |
| CN103735689B (en) | A kind of natural drug composition is preparing the application in anoxia enduring medicine and health product | |
| CN105031468A (en) | Sharpleaf galangal fruit extract capable of treating chronic kidney diseases and applications thereof | |
| CN101129627A (en) | Traditional Chinese medicine formulated product for treating post partum toxin fever | |
| CN104739940B (en) | Treat the Chinese prescription of rheumatism bone disease and its preparation method of Chinese patent drug | |
| CN103948896A (en) | Composition for resisting altitude stress and application of composition | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN104940666A (en) | Pharmaceutical composition having anti-hypoxia effect and preparation method | |
| CN104056207B (en) | Traditional Chinese medicine combination for treating stomach cancer and preparation method for same | |
| CN113521206B (en) | Traditional Chinese medicine composition containing burdock | |
| CN105663404A (en) | Medicine for treating endometritis | |
| CN104013815A (en) | Traditional Chinese medicine for treating recurrent oral ulcer due to deficiency of yin and excess of heat and preparation method of traditional Chinese medicine | |
| CN102284036A (en) | Gujinwan capsule and preparation method thereof | |
| CN102357147A (en) | Chinese medicine composite tincture capable of diminishing inflammation, relieving pain and preventing viruses and preparation method thereof | |
| CN101933990A (en) | Application of galium verum L. general flavone in preparing medicicament of alpha-glucuronide inhibitor | |
| CN101816708A (en) | Treat rheumatismal Chinese medicine composition and preparation method thereof | |
| CN101375954A (en) | Medicament composition, preparation method thereof and use | |
| CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
| CN104666461A (en) | Medicament for treating rheumatoid arthritis and preparation method of medicament | |
| CN104998019A (en) | Traditional Chinese medicine composition for promoting blood circulation for removing blood stasis and reliving bleeding and pain | |
| CN105012642A (en) | Preparation method of traditional Chinese medicine composition capable of promoting blood circulation to remove blood stasis, and stopping bleeding and relieving pain | |
| CN1358529A (en) | Medicine composition containing yak bone for treating rhenmatism and method for making same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20200121 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |